Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do vaccines still work during lymphoma treatment? new study aims to find out

NCT ID NCT06070961

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to understand if vaccines remain effective during treatment, which could help improve vaccination strategies for these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors understand how well vaccines protect follicular lymphoma patients during treatment, guiding future vaccination schedules.
What could go wrong
This is a small, observational study (56 participants) that only measures immune markers, not actual protection from infection. Results may not apply to all patients or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

56 people

The number who actually took part.

Started

May 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients affected by Follicular Lymphoma undergoing frontline induction immuno-chemotherapy and anti-CD20 maintenance within the prospective FIL\_FOLL19 study

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Enrolment in FIL\_FOLL19 study 2. Previous vaccination for COVID-19 (at least 3 doses) 3. Availability of informations about COVID-19 and other vaccines previously administered (vaccination records) 4. Willingness to comply with blood collection timepoints required for vaccination immunity evaluation 5. Signature of specific informed consent form Exclusion Criteria: None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Follicular lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 diphtheria follicular lymphoma herpes zoster lymphoma tetanus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Follicular lymphoma

Contacts and locations

Locations

  • A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia

    Alessandria, IT, Italy

  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia

    Torino, IT, Italy

  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U

    Torino, IT, Italy

  • A.O.U. Maggiore della Carità di Novara - S.C.D.U. Ematologia

    Novara, IT, Italy

  • A.O.U. Senese - U.O.C. Ematologia

    Siena, Italy

  • ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia

    Milan, IT, Italy

  • Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico

    Avellino, AV, 83100, Italy

  • Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

    Florence, Italy

  • Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia

    Reggio Emilia, Italy

  • IRCCS Policlinico San Matteo - Divisione di Ematologia

    Pavia, IT, Italy

  • Nuovo Ospedale degli Infermi, SSD Ematologia

    Biella, IT, Italy

  • Ospedale Guglielmo da Saliceto - U.O. Ematologia

    Piacenza, IT, Italy

  • Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda - Ematologia

    Milan, IT, Italy

  • Ospedale delle Croci, Ematologia

    Ravenna, RA, 48121, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.